Nab-paclitaxel,Cyclophosphamide
ImmunityBio
[]
#immunitybio announces presentation at #ascogi23 of fully enrolled trial in third-line and greater #pancreaticcancer and update on #fda type b meetings regarding paths to registration $ibrx 
Follow top-line development in the oncology commercial domain through our award winning intelligence service, 1stOncology.